Immunome (NASDAQ:IMNM) Hits New 52-Week Low – Here’s What Happened

Shares of Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week low on Wednesday . The company traded as low as $8.30 and last traded at $8.46, with a volume of 23224 shares trading hands. The stock had previously closed at $8.36.

Analyst Ratings Changes

IMNM has been the subject of several analyst reports. Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Monday, March 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $27.17.

Immunome Trading Up 1.7 %

The firm has a fifty day moving average of $9.89 and a 200 day moving average of $11.66. The company has a market capitalization of $678.26 million, a P/E ratio of -1.05 and a beta of 1.93.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new position in Immunome in the fourth quarter valued at about $70,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Immunome in the 4th quarter worth $75,000. AlphaQuest LLC increased its stake in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Immunome in the 4th quarter worth $95,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.